Study of ABT-869 in Subjects With Advanced Non-small Cell Lung Cancer (NSCLC)

NCT00517790 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

140

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-Small Cell Lung Cancer (NSCLC)

Interventions

DRUG: ABT-869 .25 mg/kg
DRUG: ABT-869 0.10 mg/kg

Sponsor

AbbVie (prior sponsor, Abbott)

Collaborators

[object Object]